A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap.

ABSTRACT: Aetiological and clinical heterogeneity is increasingly recognized as a common characteristic of Alzheimer's disease and related dementias. This heterogeneity complicates diagnosis, treatment, and the design and testing of new drugs. An important line of research is discovery of multimodal biomarkers that will facilitate the targeting of subpopulations with homogeneous pathophysiological signatures. High-throughput 'omics' are unbiased data-driven techniques that probe the complex aetiology of Alzheimer's disease from multiple levels (e.g. network, cellular, and molecular) and thereby account for pathophysiological heterogeneity in clinical populations. This review focuses on data reduction analyses that identify complementary disease-relevant perturbations for three omics techniques: neur

SUBMITTER: Badhwar A 

PROVIDER: S-EPMC7241959 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature